Multiple Screening: a tool to identify cognitive deficits in individuals with Multiple Sclerosis in an early stage. The acquisition of normative data.

Completed

Conditions: Cognition
attention
memory and concentration
10012303

Registration Number: NL-OMON45675

Lead Sponsor: Vrije Universiteit Medisch Centrum

Brief Summary: Not available

Detailed Description: Not available

Recruitment & Eligibility

Status: Completed

Sex: Not specified

Target Recruitment: 300

Inclusion Criteria

The MS patients:
- All patients are diagnosed with clinically definite MS following the revised McDonald criteria (Polman et al., 2011).
- Patients are at least 18 years of age
- The patients are able to use an iPad.
- Patients are willing to sign an informed consent prior to participation.;The healthy participants:
- Healthy participants (no neurological and/or psychiatric illnesses) that are at least 18 years of age.
- The participants are able to use an iPad.
- The first sixty participants are willing to do both the digital as the paper-and-pencil version of the tests that are in the Multiple Screening app.

Exclusion Criteria

- Neurological (other than MS for the patients) and psychiatric illnesses.
- A history of drug- and/or alcohol abuse (including present)
- Inability to execute a neuropsychological examination on an iPad (e.g. due to eye-related problems, fatigue, language barrier or motor difficulties.

Study & Design

Study Type: Observational non invasive

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Determining the understandability, feasibility, and independence of using the<br /><br>Multiple Screening app in MS patients, in that the fully understandable,<br /><br>feasible, and independent Multiple Screening app can be executed by a group of<br /><br>healthy participants to determine normative data for the digital cognitive<br /><br>tests within the app. The scores on the paper-and-pencil version and the<br /><br>digital version of the tests will subsequently be compared by administering<br /><br>both versions of the tests in sixty participants.</p><br>

Secondary Outcome Measures